Compass Capital Management Inc. boosted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.8% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 297,890 shares of the company’s stock after purchasing an additional 8,244 shares during the period. Johnson & Johnson comprises 3.5% of Compass Capital Management Inc.’s investment portfolio, making the stock its 24th biggest position. Compass Capital Management Inc.’s holdings in Johnson & Johnson were worth $46,173,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in JNJ. DORCHESTER WEALTH MANAGEMENT Co boosted its stake in Johnson & Johnson by 8.6% in the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after acquiring an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P boosted its stake in Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares during the last quarter. AMI Investment Management Inc. boosted its stake in Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after acquiring an additional 1,475 shares during the last quarter. Equitable Holdings Inc. boosted its stake in Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after acquiring an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd boosted its stake in Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after acquiring an additional 20,528 shares during the last quarter. 67.57% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on JNJ shares. Barclays boosted their target price on shares of Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research note on Monday, July 24th. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. StockNews.com started coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $187.00 target price on shares of Johnson & Johnson in a report on Friday, July 21st. Eight research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $171.60.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.59 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.76 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.73%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 96.36%.
Insider Activity at Johnson & Johnson
In related news, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,163 shares of company stock valued at $7,928,856. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 7/24 – 7/28
- How to Choose Top Rated Stocks
- Can SAIA Continue its Stratospheric Rally?
- Canada Bond Market Holiday: How to Invest and Trade
- Why Markets Are Loving Exxon Mobil, Despite The Earnings Dip
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
